Prognostic factors predicting recurrence in borderline ovarian tumors

Tzu I. Wu, Chyi Long Lee, Meng Y. Wu, Swei Hsueh, Kuan G. Huang, Chi J. Yeh, Chyong Huey Lai

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective: We aimed to investigate outcome of borderline ovarian tumors (BOTs) with respect to methods and extent of surgical approach and to evaluate prognostic factors. Methods: A retrospective study included consecutive patients with BOT treated from 1984 to 2008. These cases were confirmed by histological review. The influence of clinico-pathological characteristics upon recurrence and death were analyzed by independent sample t test, Chi-square test, logistic regression model, and Cox proportional hazard model. Results: A total of 233 patients were enrolled, 214 in Stage I, 11 Stage II and 8 Stage III. There were 21 relapses, only 5 of which died of disease. 5-year and 10-year overall survival were 97.6% and 96.4%, and recurrence-free survival rates (RFS) were 92.7% and 88.2%, respectively. Median follow-up time for survivors was 81 (range, 0.5-295) months. Median time to recurrence was 31 (range, 5.5-181) months. In multivariate analysis, Stage II/III, cystectomy and higher pretreatment serum CA-125 level ( ≥ 144 U/mL) were selected for a model predicting 5-year RFS, where risk factor = 0, 1, and 2-3 had odds ratios of 1, 14.9, and 113.3, respectively (p <0.001). Replacing stage with peritoneal implants, the latter two factors along with invasive peritoneal implants were selected. Of the 5 cases died of disease, all had invasive recurrences. Initial laparoscopic or laparotomy approach had no influence on prognosis. Conclusions: Although BOT has an excellent prognosis, they are not exempted from a risk of recurrence. Stage II/III (or invasive implants), cystectomy and higher pre-operative serum CA-125 were independent variables predicting recurrence. Crown

Original languageEnglish
Pages (from-to)237-241
Number of pages5
JournalGynecologic Oncology
Volume114
Issue number2
DOIs
Publication statusPublished - Aug 2009
Externally publishedYes

Fingerprint

Recurrence
Neoplasms
Cystectomy
Survival Rate
Logistic Models
Chi-Square Distribution
Crowns
Serum
Proportional Hazards Models
Laparotomy
Survivors
Multivariate Analysis
Retrospective Studies
Odds Ratio
Survival

Keywords

  • Borderline ovarian tumor
  • CA 125
  • Cystectomy
  • Recurrence
  • Stage

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Wu, T. I., Lee, C. L., Wu, M. Y., Hsueh, S., Huang, K. G., Yeh, C. J., & Lai, C. H. (2009). Prognostic factors predicting recurrence in borderline ovarian tumors. Gynecologic Oncology, 114(2), 237-241. https://doi.org/10.1016/j.ygyno.2009.05.018

Prognostic factors predicting recurrence in borderline ovarian tumors. / Wu, Tzu I.; Lee, Chyi Long; Wu, Meng Y.; Hsueh, Swei; Huang, Kuan G.; Yeh, Chi J.; Lai, Chyong Huey.

In: Gynecologic Oncology, Vol. 114, No. 2, 08.2009, p. 237-241.

Research output: Contribution to journalArticle

Wu, TI, Lee, CL, Wu, MY, Hsueh, S, Huang, KG, Yeh, CJ & Lai, CH 2009, 'Prognostic factors predicting recurrence in borderline ovarian tumors', Gynecologic Oncology, vol. 114, no. 2, pp. 237-241. https://doi.org/10.1016/j.ygyno.2009.05.018
Wu, Tzu I. ; Lee, Chyi Long ; Wu, Meng Y. ; Hsueh, Swei ; Huang, Kuan G. ; Yeh, Chi J. ; Lai, Chyong Huey. / Prognostic factors predicting recurrence in borderline ovarian tumors. In: Gynecologic Oncology. 2009 ; Vol. 114, No. 2. pp. 237-241.
@article{9f1aa3cefe064c6fb9897b575cdf3a49,
title = "Prognostic factors predicting recurrence in borderline ovarian tumors",
abstract = "Objective: We aimed to investigate outcome of borderline ovarian tumors (BOTs) with respect to methods and extent of surgical approach and to evaluate prognostic factors. Methods: A retrospective study included consecutive patients with BOT treated from 1984 to 2008. These cases were confirmed by histological review. The influence of clinico-pathological characteristics upon recurrence and death were analyzed by independent sample t test, Chi-square test, logistic regression model, and Cox proportional hazard model. Results: A total of 233 patients were enrolled, 214 in Stage I, 11 Stage II and 8 Stage III. There were 21 relapses, only 5 of which died of disease. 5-year and 10-year overall survival were 97.6{\%} and 96.4{\%}, and recurrence-free survival rates (RFS) were 92.7{\%} and 88.2{\%}, respectively. Median follow-up time for survivors was 81 (range, 0.5-295) months. Median time to recurrence was 31 (range, 5.5-181) months. In multivariate analysis, Stage II/III, cystectomy and higher pretreatment serum CA-125 level ( ≥ 144 U/mL) were selected for a model predicting 5-year RFS, where risk factor = 0, 1, and 2-3 had odds ratios of 1, 14.9, and 113.3, respectively (p <0.001). Replacing stage with peritoneal implants, the latter two factors along with invasive peritoneal implants were selected. Of the 5 cases died of disease, all had invasive recurrences. Initial laparoscopic or laparotomy approach had no influence on prognosis. Conclusions: Although BOT has an excellent prognosis, they are not exempted from a risk of recurrence. Stage II/III (or invasive implants), cystectomy and higher pre-operative serum CA-125 were independent variables predicting recurrence. Crown",
keywords = "Borderline ovarian tumor, CA 125, Cystectomy, Recurrence, Stage",
author = "Wu, {Tzu I.} and Lee, {Chyi Long} and Wu, {Meng Y.} and Swei Hsueh and Huang, {Kuan G.} and Yeh, {Chi J.} and Lai, {Chyong Huey}",
year = "2009",
month = "8",
doi = "10.1016/j.ygyno.2009.05.018",
language = "English",
volume = "114",
pages = "237--241",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Prognostic factors predicting recurrence in borderline ovarian tumors

AU - Wu, Tzu I.

AU - Lee, Chyi Long

AU - Wu, Meng Y.

AU - Hsueh, Swei

AU - Huang, Kuan G.

AU - Yeh, Chi J.

AU - Lai, Chyong Huey

PY - 2009/8

Y1 - 2009/8

N2 - Objective: We aimed to investigate outcome of borderline ovarian tumors (BOTs) with respect to methods and extent of surgical approach and to evaluate prognostic factors. Methods: A retrospective study included consecutive patients with BOT treated from 1984 to 2008. These cases were confirmed by histological review. The influence of clinico-pathological characteristics upon recurrence and death were analyzed by independent sample t test, Chi-square test, logistic regression model, and Cox proportional hazard model. Results: A total of 233 patients were enrolled, 214 in Stage I, 11 Stage II and 8 Stage III. There were 21 relapses, only 5 of which died of disease. 5-year and 10-year overall survival were 97.6% and 96.4%, and recurrence-free survival rates (RFS) were 92.7% and 88.2%, respectively. Median follow-up time for survivors was 81 (range, 0.5-295) months. Median time to recurrence was 31 (range, 5.5-181) months. In multivariate analysis, Stage II/III, cystectomy and higher pretreatment serum CA-125 level ( ≥ 144 U/mL) were selected for a model predicting 5-year RFS, where risk factor = 0, 1, and 2-3 had odds ratios of 1, 14.9, and 113.3, respectively (p <0.001). Replacing stage with peritoneal implants, the latter two factors along with invasive peritoneal implants were selected. Of the 5 cases died of disease, all had invasive recurrences. Initial laparoscopic or laparotomy approach had no influence on prognosis. Conclusions: Although BOT has an excellent prognosis, they are not exempted from a risk of recurrence. Stage II/III (or invasive implants), cystectomy and higher pre-operative serum CA-125 were independent variables predicting recurrence. Crown

AB - Objective: We aimed to investigate outcome of borderline ovarian tumors (BOTs) with respect to methods and extent of surgical approach and to evaluate prognostic factors. Methods: A retrospective study included consecutive patients with BOT treated from 1984 to 2008. These cases were confirmed by histological review. The influence of clinico-pathological characteristics upon recurrence and death were analyzed by independent sample t test, Chi-square test, logistic regression model, and Cox proportional hazard model. Results: A total of 233 patients were enrolled, 214 in Stage I, 11 Stage II and 8 Stage III. There were 21 relapses, only 5 of which died of disease. 5-year and 10-year overall survival were 97.6% and 96.4%, and recurrence-free survival rates (RFS) were 92.7% and 88.2%, respectively. Median follow-up time for survivors was 81 (range, 0.5-295) months. Median time to recurrence was 31 (range, 5.5-181) months. In multivariate analysis, Stage II/III, cystectomy and higher pretreatment serum CA-125 level ( ≥ 144 U/mL) were selected for a model predicting 5-year RFS, where risk factor = 0, 1, and 2-3 had odds ratios of 1, 14.9, and 113.3, respectively (p <0.001). Replacing stage with peritoneal implants, the latter two factors along with invasive peritoneal implants were selected. Of the 5 cases died of disease, all had invasive recurrences. Initial laparoscopic or laparotomy approach had no influence on prognosis. Conclusions: Although BOT has an excellent prognosis, they are not exempted from a risk of recurrence. Stage II/III (or invasive implants), cystectomy and higher pre-operative serum CA-125 were independent variables predicting recurrence. Crown

KW - Borderline ovarian tumor

KW - CA 125

KW - Cystectomy

KW - Recurrence

KW - Stage

UR - http://www.scopus.com/inward/record.url?scp=67549103662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67549103662&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2009.05.018

DO - 10.1016/j.ygyno.2009.05.018

M3 - Article

VL - 114

SP - 237

EP - 241

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -